Piper Sandler Begins Coverage on Upstream Bio (NASDAQ:UPB)

Piper Sandler initiated coverage on shares of Upstream Bio (NASDAQ:UPB - Free Report) in a research note published on Tuesday morning, MarketBeat reports. The brokerage issued an overweight rating and a $75.00 price objective on the stock.

Other equities analysts also recently issued reports about the stock. William Blair assumed coverage on shares of Upstream Bio in a report on Tuesday. They set an "outperform" rating on the stock. TD Cowen began coverage on Upstream Bio in a research note on Tuesday. They issued a "buy" rating on the stock. Finally, JPMorgan Chase & Co. began coverage on Upstream Bio in a research note on Tuesday. They issued an "overweight" rating and a $38.00 price objective for the company.

Upstream Bio Price Performance

NASDAQ:UPB traded up $2.55 during trading hours on Tuesday, reaching $27.70. The company had a trading volume of 464,751 shares, compared to its average volume of 349,379. Upstream Bio has a 1-year low of $20.74 and a 1-year high of $28.98.

Insider Transactions at Upstream Bio

In other Upstream Bio news, major shareholder Ai Upstream Llc purchased 1,175,000 shares of the firm's stock in a transaction dated Tuesday, October 15th. The shares were acquired at an average price of $17.00 per share, with a total value of $19,975,000.00. Following the purchase, the insider now directly owns 1,175,000 shares in the company, valued at approximately $19,975,000. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. In other Upstream Bio news, Director Erez Chimovits purchased 825,000 shares of the firm's stock in a transaction on Tuesday, October 15th. The stock was bought at an average cost of $17.00 per share, with a total value of $14,025,000.00. Following the acquisition, the director now directly owns 4,554,873 shares of the company's stock, valued at approximately $77,432,841. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Ai Upstream Llc acquired 1,175,000 shares of the company's stock in a transaction dated Tuesday, October 15th. The stock was acquired at an average price of $17.00 per share, for a total transaction of $19,975,000.00. Following the acquisition, the insider now owns 1,175,000 shares in the company, valued at approximately $19,975,000. The disclosure for this purchase can be found here.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.